Oral Insulin AFREZZA Successful at Controlling Blood Sugar Levels in Type 1 Diabetes Patients

MannKind announced that results of a new 16-week trial show that the investigational ultra rapid acting mealtime insulin, AFREZZA (insulin human [rDNA origin]) Inhalation Powder, combined with basal insulin, is clearly non-inferior to standard therapy insulin lispro, a rapid acting insulin (also combined with basal insulin), in reducing HbA1c levels in subjects with inadequately controlled type 1 diabetes. In addition, patients treated with AFREZZA had statistically significant lower rates of hypoglycemia, post-prandial glucose levels when measured at 30, 60, 90 and 120 minutes, and fasting blood glucose levels when compared to subcutaneously injected insulin lispro.

ASweetLife Team

Trump To Slash Insulin Costs for Medicare Patients President Trump has announced that monthly co-pays for Medicare insulin will be capped at just $35, beginning in January 2021. "This is a big day for seniors," President Trump said…
COVID-19: Why Blood Sugar Matters The more we learn about COVID-19, the more we learn how critical blood sugar management is. In late April, the prestigious medical journal The Lancet published this eye-opening statement: People…
High Blood Sugar and Cognitive Decline in Teens You may have heard that high blood sugars can make your feel slow, fuzzy or tired. Perhaps you’ve experienced it yourself. The research suggests that this weary, leaden feeling could…
Will the Next Apple Watch Monitor Your Blood Sugar? The diabetes world is abuzz with reports that the new Apple Watch will include a non-invasive blood sugar sensor. Non-invasive glucose monitoring technology is considered a holy grail of the…
Why the ADA Lowered Blood Sugar Targets for Children Last year, when the American Diabetes Association (ADA) updated its annual “Standards of Medical Care in Diabetes” document—the set of recommendations that largely guides diabetes care in America—the organization made…